New ablation catheter technology could propel PCA (percutaneous catheter ablation) uptake, says Endosense CEO
This article was originally published in Clinica
Executive Summary
A next-generation ablation catheter designed to enhance the safety and effectiveness of percutaneous catheter ablation (PCA) treatment for atrial fibrillation (AF) is en route to market, following a recent SFr26m ($20m) investment from leading venture capital firms 3i and Neomed.